Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Jamie Steele

Nurse Practitioner, Gerontology Venice, FL Nurse Practitioner

NPI 1366933079 CMS profile 10759176

836 Sunset Lake Blvd, Venice, FL 34292

Open in the dashboard

General payments

$7,733

331 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jamie Steele of Venice, FL is reported in the CMS Open Payments database as having received $7,733 across 331 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,758 122
2024 General $2,803 123
2023 General $2,172 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jamie Steele
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Jamie Steele were reported at $2,758. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Jamie Steele Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $133 $44–$396 $132
2022 $0 $142 $48–$452 $149
2023 $2,172 $158 $53–$482 $160
2024 $2,803 $171 $55–$533 $164
2025 $2,758 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Incyte Corporation $556 20 payments
  2. Merck Sharp & Dohme Corporation $473 21 payments
  3. E.R. Squibb & Sons, L.L.C. $411 27 payments
  4. Lilly USA, LLC $394 13 payments
  5. Pfizer Inc. $393 17 payments
  6. Astellas Pharma US Inc $379 11 payments
  7. Daiichi Sankyo Inc. $377 14 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $373 15 payments
  9. AstraZeneca Pharmaceuticals LP $356 17 payments
  10. Exelixis Inc. $320 8 payments
  11. Other $3,701 168 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $7,069 324 payments
  2. Education $664 7 payments
Products named General payments · program years 2023–2025
  1. JAKAFI $438 15 payments
  2. KEYTRUDA $436 19 payments
  3. ENHERTU $377 14 payments
  4. OPDIVO $370 25 payments
  5. JAYPIRCA $284 11 payments
  6. Doptelet $272 6 payments
  7. Nubeqa $205 7 payments
  8. VERZENIO $189 9 payments
  9. NINLARO $177 8 payments
  10. INLYTA $154 6 payments
  11. Other $5,523 268 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

331 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record